Eli Lilly and Company (NYSE:LLY) Stake Decreased by Jackson Square Capital LLC

Jackson Square Capital LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 5.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,877 shares of the company’s stock after selling 1,318 shares during the quarter. Eli Lilly and Company comprises about 5.0% of Jackson Square Capital LLC’s portfolio, making the stock its 4th largest position. Jackson Square Capital LLC’s holdings in Eli Lilly and Company were worth $20,268,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its holdings in Eli Lilly and Company by 19.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares in the last quarter. Quent Capital LLC increased its position in Eli Lilly and Company by 5.3% during the 1st quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock valued at $3,846,000 after purchasing an additional 249 shares during the period. W.H. Cornerstone Investments Inc. increased its position in Eli Lilly and Company by 44.6% during the 1st quarter. W.H. Cornerstone Investments Inc. now owns 1,213 shares of the company’s stock valued at $944,000 after purchasing an additional 374 shares during the period. Manchester Capital Management LLC increased its position in Eli Lilly and Company by 33.9% during the 1st quarter. Manchester Capital Management LLC now owns 4,049 shares of the company’s stock valued at $3,150,000 after purchasing an additional 1,025 shares during the period. Finally, Advisory Services Network LLC increased its position in Eli Lilly and Company by 5.1% during the 1st quarter. Advisory Services Network LLC now owns 45,528 shares of the company’s stock valued at $35,418,000 after purchasing an additional 2,225 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $776.47 on Thursday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a 50 day simple moving average of $901.75 and a two-hundred day simple moving average of $867.32. The stock has a market cap of $737.11 billion, a price-to-earnings ratio of 83.94, a PEG ratio of 3.05 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The business’s revenue was up 20.4% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Wall Street Analyst Weigh In

A number of research firms have commented on LLY. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,008.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.